These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 30059414)
1. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know? Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414 [TBL] [Abstract][Full Text] [Related]
3. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148 [TBL] [Abstract][Full Text] [Related]
4. Biosimilars in rheumatology: understanding the rigor of their development. Goel N; Chance K Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704 [TBL] [Abstract][Full Text] [Related]
5. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries. El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region. Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644 [TBL] [Abstract][Full Text] [Related]
7. The changing landscape of biosimilars in rheumatology. Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144 [TBL] [Abstract][Full Text] [Related]
8. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Schulze-Koops H; Skapenko A Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543 [TBL] [Abstract][Full Text] [Related]
9. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey. Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288 [TBL] [Abstract][Full Text] [Related]
10. Era of biosimilars in rheumatology: reshaping the healthcare environment. Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars in pediatric rheumatology and their introduction into routine care. Aragon Cuevas O; Hedrich CM Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950 [TBL] [Abstract][Full Text] [Related]
12. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Castañeda-Hernández G; Szekanecz Z; Mysler E; Azevedo VF; Guzman R; Gutierrez M; Rodríguez W; Karateev D Joint Bone Spine; 2014 Dec; 81(6):471-7. PubMed ID: 24956990 [TBL] [Abstract][Full Text] [Related]
13. Biosimilars in rheumatology: current perspectives and lessons learnt. Dörner T; Kay J Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080 [TBL] [Abstract][Full Text] [Related]
14. Use of Biologics and Biosimilars in Rheumatology. Sharma SK J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745 [TBL] [Abstract][Full Text] [Related]
15. Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. Scheinberg M; Pineda C; Castañeda-Hernández G; Zarbá JJ; Damião A; Arantes LH; Jacobs I MAbs; 2018; 10(6):827-842. PubMed ID: 30156950 [TBL] [Abstract][Full Text] [Related]
16. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America. de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455 [TBL] [Abstract][Full Text] [Related]
17. Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region. Alnaqbi KA; Al Adhoubi N; Aldallal S; Al Emadi S; Al-Herz A; El Shamy AM; Hannawi S; Omair MA; Saad SA; Kvien TK BioDrugs; 2024 May; 38(3):449-463. PubMed ID: 38402494 [TBL] [Abstract][Full Text] [Related]
18. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Uhlig T; Goll GL Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542 [TBL] [Abstract][Full Text] [Related]
19. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016. Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650 [TBL] [Abstract][Full Text] [Related]